Verrica Pharmaceuticals inc (VRCA) Reports Q4 Earnings

Verrica Pharmaceuticals inc (VRCA) reported a Q4 2025 adjusted loss of $0.51 per share. Top-line revenue was $5.1M. The dermatology therapeutics company develops and sells medications for the treatment of skin diseases in the United States.

Verrica’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts. The company has also completed phase II clinical trials for treating external genital warts and molluscum contagiosum.